Enzyme-linked immunosorbent assay (ELISA) is an analytic biochemical assay that utilizes enzyme-linked antibodies on a microwell platform to quantitate specific proteins within biological samples. Visual detection is then achieved by adding the enzyme’s substrate, which causes a color-changing reaction to occur. There are three different types of ELISA that are most commonly used: indirect ELISA, sandwich ELISA and competitive ELISA. These assays are extremely useful for high-throughput diagnostic screenings drug testing.
Novus offers a range of support options for ELISA when you buy a product to help you with your ELISA experiment including:
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB120-6106SS | |||
| Azide and BSA Free | NBP2-80778 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| FITC | NB120-6641-1000ug | |||
![Western Blot: hnRNP L Antibody (4D11) [NB120-6106] - analysis of hnRNP L in HEK whole cell lysate using anti-hnRNP L antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/hnRNP-L-Antibody-4D11-Western-Blot-NB120-6106-img0005.jpg "Western Blot: hnRNP L Antibody (4D11) [NB120-6106] - analysis of hnRNP L in HEK whole cell lysate using anti-hnRNP L antibody. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: hnRNP L Antibody (4D11) [NB120-6106] - hnRNP L antibody was tested in HeLa cells at 5 ug/ml using a Dylight 488 conjugated secondary antibody (Green). Actin (Red) and DNA (Blue) were counterstained using Phalloidin 568 and DAPI.](http://images.novusbio.com/fullsize/hnRNP-L-Antibody-4D11-Immunocytochemistry-Immunofluorescence-NB120-6106-img0004.jpg)
![Immunohistochemistry-Frozen: hnRNP L Antibody (4D11) [NB120-6106]](http://images.novusbio.com/fullsize/hnRNP-L-Antibody-4D11-Immunohistochemistry-Frozen-NB120-6106-img0002.jpg)
![Western Blot: hnRNP L Antibody (4D11) [NB120-6106] - Western blot for anti-hnRNP-L on HeLa cell extracts](http://images.novusbio.com/fullsize/hnRNP-L-Antibody-4D11-Western-Blot-NB120-6106-img0001.jpg)
![Western Blot: hnRNP L Antibody (4D11) [NB120-6106] - Whole cell protein from HeLa (lane 1), A431 (lane 2), NIH-3T3 (lane 3) and PC12 (lane 4) was separated by SDS-PAGE and transferred to PVDF membrane. The membrane was probed with Anti-hnRNP L at 1 ug/ml and detected with an HRP conjugated anti-mouse secondary antibody by chemiluminescence.](http://images.novusbio.com/fullsize/hnRNP-L-Antibody-4D11-Western-Blot-NB120-6106-img0003.jpg)
![Western Blot: beta Galactosidase Antibody [NB600-305] - Analysis using FITC conjugate of NB600-305. 3) corresponding to 60 ng, 30 ng and 15 ng, respectively of b-Gal present in partially purified preparations (arrowhead). Lane 4 shows no cross reactivity with proteins present in a non-specific control E.coli lysate. Proteins were resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred to nitrocellulose and blocking using Blocking Buffer for Fluorescent Western Blotting. The membrane was probed with fluorescein conjugated anti-b-Galactosidase diluted to 1:10,000. Reaction occurred for 2 hours at room temperature.](http://images.novusbio.com/fullsize/beta-Galactosidase-Antibody-Western-Blot-NB600-305-img0017.jpg "Western Blot: beta Galactosidase Antibody [NB600-305] - Analysis using FITC conjugate of NB600-305. 3) corresponding to 60 ng, 30 ng and 15 ng, respectively of b-Gal present in partially purified preparations (arrowhead). Lane 4 shows no cross reactivity with proteins present in a non-specific control E.coli lysate. Proteins were resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred to nitrocellulose and blocking using Blocking Buffer for Fluorescent Western Blotting. The membrane was probed with fluorescein conjugated anti-b-Galactosidase diluted to 1:10,000. Reaction occurred for 2 hours at room temperature.")
![Western Blot: beta Galactosidase Antibody [NB600-305] - Analysis of a band at 117 kDa (lane 1) corresponding to b-Gal present in a partially purified preparation (arrowhead). Approximately 1 ug of protein was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. After blocking, the membrane was probed with the primary antibody diluted to 1:1,000. Reaction occurred overnight at 4 C followed by washes and reaction with a 1:10,000 dilution of IRDye 800 conjugated Gt-a-Rabbit IgG (H&L) MX10 for 45 min at room temperature (800 nm channel, green).](http://images.novusbio.com/fullsize/beta-Galactosidase-Antibody-Western-Blot-NB600-305-img0014.jpg)
![Western Blot: beta Galactosidase Antibody [NB600-305] - Lane 1 shows 80 ng and lane 2 shows 20 ng loaded onto gel. Results for non-reducing conditions of SDS-PAGE prior to transfer to nitrocellulose are shown on the left side of the figure; results obtainined under reducing conditions are shown on the right. Blots were blocked overnight at 4 C with Blocking Buffer for Fluorescent Western Blotting. The membrane was probed with anti-b-Galactosidase diluted to 1:10,000. Reaction occurred overnight at 4C. Dylight649 conjugated Gt-a-anti-Rabbit IgG was used for detection.](http://images.novusbio.com/fullsize/beta-Galactosidase-Antibody-Western-Blot-NB600-305-img0015.jpg)
![Western Blot: beta Galactosidase Antibody [NB600-305] - Shows a band at 117 kDa (lanes 1 - 3) corresponding to 60 ng, 30 ng and 15 ng, respectively of b-Gal present in partially purified preparations (arrowhead). Lane 4 shows no cross reactivity with proteins present in a non-specific control E.coli lysate. Proteins were resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred to nitrocellulose and blocking using Blocking Buffer for Fluorescent Western Blotting. The membrane was probed with fluorescein conjugated anti-b-Galactosidase diluted to 1:10,000. Reaction occurred for 2 hours at room temperature.](http://images.novusbio.com/fullsize/beta-Galactosidase-Antibody-Western-Blot-NB600-305-img0016.jpg)
![Western Blot of Rabbit Anti-Beta-Galactosidase Antibody. Lane 1: Beta-Galactosidase Reduced [0.1ug]. Lane 2: Opal Prestained Molecular Weight Marker](http://images.novusbio.com/fullsize/nb600-305_rabbit-polyclonal-beta-galactosidase-antibody-24520231056468.jpg)
![Western Blot of Rabbit Anti-Beta-Galactosidase Antibody. Lane 1: partially purified preparation b-Galactosidase [1.0ug]. Lane 2: Molecular Weight Marker. Primary Antibody: Anti-Beta-Galactosidase at 1:1000 overnight at 2-8C. Secondary Antibody: Goat Anti-Rabbit IgG IRDye(R)800](http://images.novusbio.com/fullsize/nb600-305_rabbit-polyclonal-beta-galactosidase-antibody-2552023131130.jpg)
![Western Blot: ODF2 Antibody (1A1) [H00004957-M01] - Detection against Immunogen (36.63 KDa) .](http://images.novusbio.com/fullsize/ODF2-Antibody-1A1-Western-Blot-H00004957-M01-img0006.jpg "Western Blot: ODF2 Antibody (1A1) [H00004957-M01] - Detection against Immunogen (36.63 KDa) .")
![Immunocytochemistry/Immunofluorescence: ODF2 Antibody (1A1) [H00004957-M01] - The localization and function of DYF-19 are highly conserved In IMCD3 cells, FBF1 localizes above rootlet and subdistal appendage protein ODF2 and completely colocalizes with distal appendage protein CEP164. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms3750) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ODF2-Antibody-1A1-Immunocytochemistry-Immunofluorescence-H00004957-M01-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: ODF2 Antibody (1A1) [H00004957-M01] - Co-staining of ODF2 (Cy3), DAPI and r-tubulin (Alexa Fluor 488) in RPE1 cell line. ODF2 stains the subdistal appendage of mother centriole. Cells were fixed with cold methanol, 10min. Blocked with 3% BSA for 30min at room temperature. ODF2 antibody was used at 1:100. Image from verified customer review.](http://images.novusbio.com/fullsize/ODF2-Antibody-1A1-Immunocytochemistry-Immunofluorescence-H00004957-M01-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: ODF2 Antibody (1A1) [H00004957-M01] - Analysis of monoclonal antibody to ODF2 on HeLa cell . Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/ODF2-Antibody-1A1-Immunocytochemistry-Immunofluorescence-H00004957-M01-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: ODF2 Antibody (1A1) [H00004957-M01] - The localization & function of DYF-19 are highly conservedEither endogenous (a) or overexpressed (b) FBF1, the mammalian homolog of worm DYF-19, localizes specifically on one centriole with a ring-like pattern in IMCD3 cells. c, FBF1 localizes at the ciliary base, above the basal body. d, In IMCD3 cells, FBF1 localizes above rootlet & subdistal appendage protein ODF2 & completely colocalizes with distal appendage protein CEP164. e, Immuno-EM demonstrates that FBF1 localizes specifically to distal appendages of mother centrioles. f–h, Knock-down of FBF1 leads to severely truncated cilia in most RNAi-treated hTERT-RPE cells. Data are represented as mean of 3 independent experiments (n=200) & error bars indicate s.d. Significant differences were identified by the Student’s t-test. *P<0.001. i & j, The IFT-B component IFT88, but not the IFT-A component IFT140, enters the truncated cilia of FBF1-knockdown hTERT-RPE cells. Arrows indicate the tips of truncated cilia. k, Endogenous IFT54 immunoprecipitates with FBF1 in hTERT-RPE cells. l, HEK293 cells were transiently transfected with FLAG-HA-tagged FBF1, & 48 hours later, cells were subjected to immunoprecipitation using normal mouse IgG (mIgG) or anti-IFT54 antibody. 50 μg protein were loaded into each lane. Bars: c, 1μm; e, 200 nm; others, 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24231678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00004957-m01_mouse-monoclonal-odf2-antibody-1a1-310202415482244.jpg)
![Western Blot: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Analysis of CSE1L expression in Hela S3 NE (Cat # L013V3).](http://images.novusbio.com/fullsize/CSE1L-CAS-Exportin-2-Antibody-3D8-Western-Blot-H00001434-M08-img0013.jpg "Western Blot: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Analysis of CSE1L expression in Hela S3 NE (Cat # L013V3).")
![Immunocytochemistry/Immunofluorescence: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Analysis of monoclonal antibody to CSE1L on HeLa cell. Antibody concentration 10 ug/mL.](http://images.novusbio.com/fullsize/CSE1L-CAS-Exportin-2-Antibody-3D8-Immunocytochemistry-Immunofluorescence-H00001434-M08-img0010.jpg)
![Immunohistochemistry-Paraffin: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Mouse prostate tissue section stained with primary antibody for 10 hrs. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CSE1L-CAS-Exportin-2-Antibody-3D8-Immunohistochemistry-Paraffin-H00001434-M08-img0014.jpg)
![Immunohistochemistry-Paraffin: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Analysis of monoclonal antibody to CSE1L on FFPE human prostate. Antibody concentration 3 ug/mL.](http://images.novusbio.com/fullsize/CSE1L-CAS-Exportin-2-Antibody-3D8-Immunohistochemistry-Paraffin-H00001434-M08-img0012.jpg)
![ELISA: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Detection limit for recombinant GST tagged CSE1L is approximately 3ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/CSE1L-CAS-Exportin-2-Antibody-3D8-ELISA-H00001434-M08-img0005.jpg)
![Western Blot: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Vemurafenib treatment inhibits the phosphorylation of CSE1L & ERK1/2. a Vemurafenib treatment inhibited the phosphorylation of ERK1/2 & CSE1L. The levels of hyper-phosphorylated CSE1L, hypo-phosphorylated CSE1L, & phospho-ERK1/2 in A375 melanoma cells treated with or without 1 μM vemurafenib for 24 h were subjected to immunoblotting with anti-CSE1L (clone 3D8), anti-phospho-CSE1L, & anti-phospho-ERK1/2 antibodies. beta -actin levels were assayed as a control. b A representative image shows vemurafenib-induced apoptotic body formation in A375 melanoma cells. Cells were treated with or without 1 μM vemurafenib for 72 h. c DNA fragmentation induced by vemurafenib in A375 melanoma cells treated with or without 1 μM vemurafenib for 72 h. Each immunoblot was repeated at least three times & showed similar results. The data shown here are the representative immunoblots. Image collected & cropped by CiteAb from the following publication (//www.translational-medicine.com/content/13/1/191), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00001434-m08_mouse-monoclonal-cse1l-cas-exportin-2-antibody-3d8-310202415485121.jpg)
![Western Blot: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Presence of hyper-, hypo-, & non-phosphorylated CSE1L in tumor cells as analyzed by antibodies against CSE1L & phosphorylated CSE1L. a The levels of phosphorylated & non-phosphorylated CSE1L in B16-dEV, B16-Ras, & PD98059-treated B16-Ras cells were analyzed with anti-CSE1L antibody (clone 3D8) as indicated. b The levels of phospho-CSE1L & phospho-ERK1/2 in B16-dEV, B16-CSE1L, & B16-Ras cells were analyzed with anti-phospho-CSE1L & anti-phospho-ERK1/2 antibodies as indicated. c Presence of hyper- & hypo-phosphorylated CSE1L in B16-Ras cells analyzed using lambda protein phosphatase. B16-Ras cell lysates treated with or without lambda protein phosphatase were subjected to immunoblotting with anti-CSE1L (3D8), anti-phospho-CSE1L, & anti-phospho-ERK1/2 antibodies as indicated. d Presence of non-phosphorylated & phosphorylated CSE1L as analyzed using serum-starved & serum re-fed non-cancerous cell lines. The phosphorylation of CSE1L in cell lysates from serum starved or serum starved & serum retreated HT-29 colorectal cancer cells, human foreskin fibroblast cells, NIH3T3 cells, & B16F10 melanoma cells were analyzed using the anti-CSE1L (clone 24) antibody. e Distribution of secretory phospho-CSE1L in the extracellular secretion vesicles (arrowhead) surrounding B16-Ras cells was analyzed by immunofluorescence with anti-phospho-CSE1L antibodies. Each immunoblot was repeated at least three times & showed similar results. The data shown here are the representative immunoblots. beta -actin levels were assayed as a control. pp-CSE1L hyper-phosphorylated CSE1L, p-CSE1L hypo-phosphorylated CSE1L, non-p-CSE1L non-phosphorylated CSE1L. Image collected & cropped by CiteAb from the following publication (//www.translational-medicine.com/content/13/1/191), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00001434-m08_mouse-monoclonal-cse1l-cas-exportin-2-antibody-3d8-310202415482228.jpg)
![Western Blot: CSE1L/CAS/Exportin-2 Antibody (3D8) [H00001434-M08] - Sorafenib treatment inhibits the phosphorylation of CSE1L & ERK1/2. a Sorafenib treatment inhibited the phosphorylation of ERK1/2 & CSE1L. The levels of hyper-phosphorylated CSE1L, hypo-phosphorylated CSE1L, & phospho-ERK1/2 in HT-29 colorectal cancer cells treated with or without 6 μM sorafenib for 24 h were subjected to immunoblotting with anti-CSE1L (clone 3D8), anti-phospho-CSE1L, & anti-phospho-ERK1/2 antibodies. beta -actin levels were assayed as a control. Each immunoblot was repeated at least three times & showed similar results. The data shown here are the representative immunoblots. b The cell numbers of HT-29 colorectal cancer cells treated with or without 6 μM sorafenib for 96 h were counted using trypan blue exclusion assays. The graph summarizes the results of three independent assays. Image collected & cropped by CiteAb from the following publication (//www.translational-medicine.com/content/13/1/191), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00001434-m08_mouse-monoclonal-cse1l-cas-exportin-2-antibody-3d8-310202415482255.jpg)
![Western Blot: PBR Antibody [NB100-41398] - Staining of A431 cell lysate.(35 ug protein in RIPA buffer). Antibody at 0.3 ug/mL. Detected by chemiluminescence.](http://images.novusbio.com/fullsize/PBR-Antibody-Western-Blot-NB100-41398-img0011.jpg "Western Blot: PBR Antibody [NB100-41398] - Staining of A431 cell lysate.(35 ug protein in RIPA buffer). Antibody at 0.3 ug/mL. Detected by chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: PBR Antibody [NB100-41398] - Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/PBR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-41398-img0010.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - Correlative TSPO immunohistochemistry in a primary human grade III astrocytoma xenotransplant, Tumor + White Matter Tract (40X). Image collected and cropped by CiteAb from the following publication (www.journals.plos.org/plosone/article?id=10.1371/journal.pone.0141659) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-NB100-41398-img0013.jpg)
![Flow Cytometry: PBR Antibody [NB100-41398] - Flow cytometric analysis of paraformaldehyde fixed MCF7 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/PBR-Antibody-Flow-Cytometry-NB100-41398-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: PBR Antibody [NB100-41398] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative cLontrol: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-41398-img0009.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Staining of paraffin embedded Human Colon. Antibody at 2.5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-Paraffin-NB100-41398-img0005.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Staining of paraffin embedded Human Kidney. Antibody at 5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-Paraffin-NB100-41398-img0007.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - Human tumor microarrays (TMAs). Pilocytic astrocytoma TSPO immunohistochemistry (A) and Glioblastoma multiforme TSPO immunohistochemistry (B). Image collected and cropped by CiteAb from the following publication (www.journals.plos.org/plosone/article?id=10.1371/journal.pone.0141659) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-NB100-41398-img0012.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - [18F]PBR06 selectivity in primary human grade IV glioblastoma xenotransplant.(A) Dynamic PET image (axial) pre-infusion of cold analog, with [18F]PBR06 uptake primarily confined to the tumor. (B) Dynamic PET image (axial) post-infusion, showing nearly total displacement of [18F]PBR06. (C) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). (D) Correlative TSPO immunohistochemistry, Tumor + White Matter Tract (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-31020241534322.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Human tumor microarrays (TMAs).Pilocytic astrocytoma TSPO immunohistochemistry (A) & TSPO immunohistochemical scoring (C). Glioblastoma multiforme TSPO immunohistochemistry (B) & TSPO immunohistochemical scoring (D). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415304277.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Human tumor microarrays (TMAs).Pilocytic astrocytoma TSPO immunohistochemistry (A) & TSPO immunohistochemical scoring (C). Glioblastoma multiforme TSPO immunohistochemistry (B) & TSPO immunohistochemical scoring (D). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415392564.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Primary human grade IV glioblastoma xenotransplant.(A) Dynamic PET image (coronal) of advanced tumor in the right hemisphere of the brain with [18F]PBR06 uptake confined primarily to the tumor. Arrows indicate tumor & infiltration into left hemisphere. (B) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue) [30]. (C) Correlative TSPO immunohistochemistry, Tumor + White Matter Tract (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415371958.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Primary human grade III astrocytoma xenotransplant.(A) T2-weighted MRI (coronal) visualizes advanced tumor in the right hemisphere of the brain. (B) Correlative dynamic PET image (coronal) of same advanced tumor in the right hemisphere of the brain, with [18F]PBR06 uptake primarily confined to the tumor & co-localizing with tumor tissue visualized by MRI. Top arrows indicate tumor & infiltration into left hemisphere. (C) Fused MRI (A) PET (B) image. (D) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). Correlative vimentin immunohistochemistry: (E) Gross; (F) Tumor + White Matter Tract (40X); (G) Tumor (40X). (H) Correlative dynamic PET image, axial view along yellow line in (B); arrows indicate tumor & infiltration into left hemisphere. Correlative TSPO immunohistochemistry: (I) Gross; (J) Tumor + White Matter Tract (40X); (K) Tumor (40X). (L) Dynamic PET image (axial) of control cohort. Correlative CD68 immunohistochemistry: (M) Gross; (N) Tumor + White Matter Tract (40X); (O) Tumor (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415535136.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Primary human grade III astrocytoma xenotransplant.(A) T2-weighted MRI (coronal) visualizes advanced tumor in the right hemisphere of the brain. (B) Correlative dynamic PET image (coronal) of same advanced tumor in the right hemisphere of the brain, with [18F]PBR06 uptake primarily confined to the tumor & co-localizing with tumor tissue visualized by MRI. Top arrows indicate tumor & infiltration into left hemisphere. (C) Fused MRI (A) PET (B) image. (D) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). Correlative vimentin immunohistochemistry: (E) Gross; (F) Tumor + White Matter Tract (40X); (G) Tumor (40X). (H) Correlative dynamic PET image, axial view along yellow line in (B); arrows indicate tumor & infiltration into left hemisphere. Correlative TSPO immunohistochemistry: (I) Gross; (J) Tumor + White Matter Tract (40X); (K) Tumor (40X). (L) Dynamic PET image (axial) of control cohort. Correlative CD68 immunohistochemistry: (M) Gross; (N) Tumor + White Matter Tract (40X); (O) Tumor (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-31020241612624.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - Primary human grade III astrocytoma xenotransplant.(A) T2-weighted MRI (coronal) visualizes advanced tumor in the right hemisphere of the brain. (B) Correlative dynamic PET image (coronal) of same advanced tumor in the right hemisphere of the brain, with [18F]PBR06 uptake primarily confined to the tumor & co-localizing with tumor tissue visualized by MRI. Top arrows indicate tumor & infiltration into left hemisphere. (C) Fused MRI (A) PET (B) image. (D) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). Correlative vimentin immunohistochemistry: (E) Gross; (F) Tumor + White Matter Tract (40X); (G) Tumor (40X). (H) Correlative dynamic PET image, axial view along yellow line in (B); arrows indicate tumor & infiltration into left hemisphere. Correlative TSPO immunohistochemistry: (I) Gross; (J) Tumor + White Matter Tract (40X); (K) Tumor (40X). (L) Dynamic PET image (axial) of control cohort. Correlative CD68 immunohistochemistry: (M) Gross; (N) Tumor + White Matter Tract (40X); (O) Tumor (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415533823.jpg)
![Western Blot: FoxC1 Antibody [NB100-1268] - Left- Significant upregulation of Foxc1 mRNA in Ezh2-/- Tet-ON PyVmT endpoint tumours compared to wild-type tumours. Right- Immunoblot of Ezh2+/+ or Ezh2-/- Tet-ON PyVmT endpoint tumours for Foxc1 and Ezh2 levels. Vinculin loading control. *p<0.05, two tailed t-test. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Western-Blot-NB100-1268-img0018.jpg "<b>Biological Strategies Validation. </b>Western Blot: FoxC1 Antibody [NB100-1268] - Left- Significant upregulation of Foxc1 mRNA in Ezh2-/- Tet-ON PyVmT endpoint tumours compared to wild-type tumours. Right- Immunoblot of Ezh2+/+ or Ezh2-/- Tet-ON PyVmT endpoint tumours for Foxc1 and Ezh2 levels. Vinculin loading control. *p<0.05, two tailed t-test. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL, showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/FoxC1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1268-img0015.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry: FoxC1 Antibody [NB100-1268] - Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 and EZH2. Scale bar is 100um. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Immunohistochemistry-NB100-1268-img0016.jpg)
![Flow Cytometry: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed HEK293 cells (blue line), permeabilized with 0.5% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL. IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Flow-Cytometry-NB100-1268-img0014.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FoxC1 Antibody [NB100-1268] - Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 and treated with DMSO or GSK-126 (2uM for 72h). a-Tubulin was used as a loading control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Knockdown-Validated-NB100-1268-img0017.jpg)
![Immunocytochemistry/ Immunofluorescence: FoxC1 Antibody [NB100-1268] - Breast Cancer subtype specificity of the EZH2/FOXC1 metastatic axis. a Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 & EZH2. Scale bar is 100 μm. b Significant negative correlation between FOXC1 transcript levels & EZH2 protein levels (Total intensity) quantified by immunofluorescence in human Luminal B patient samples (r = −0.52, p = 0.02). Eight different fields taken with a ×20 objective were quantified per sample. c Kaplan–Meier survival curve of relapse-free survival (RFS) of 1142 luminal B tumours with high or low FOXC1 (log rank p = 0.001). d Correlation between FOXC1 mRNA levels & the FOXC1 Signature in a cohort of 385 Luminal B patients from publicly available TCGA Breast Cancer data set. e Kaplan–Meier analysis of relapse-free survival of 1142 Luminal B tumours with high or low FOXC1 gene signature expression (log rank p = 0.0044). RFS relapse-free survival Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1268_goat-polyclonal-foxc1-antibody-310202415541964.jpg)
![Western Blot: FoxC1 Antibody [NB100-1268] - Ectopic expression of Foxc1 alters invasion but not proliferation. a Transwell invasion assay of PyVmT cells expressing exogenous Foxc1 or GFP. Experiments were performed three times, & results are displayed relative to untreated parental cell. *p < 0.05, Student’s two tailed t-tests. b CyQUANT assay measuring cellular proliferation of PyVmT cells expressing exogenous GFP or Foxc1. R.F.U relative fluorescence units. Data were normalized to the fluorescence values at time = 0. c Enumeration of lung lesions following the injection of PyVmT cells expressing exogenous Foxc1 or GFP in the tail vein of athymic nude mice. *p < 0.05, Student’s two tailed t-tests. Scale bar is 5 mm. d Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 & treated with DMSO or GSK-126 (2 μM for 72 h). alpha -Tubulin was used as a loading control. Right: Transwell invasion assay of PyVmT cells infected with shRNA targeting LacZ (control) or two different sequences targeting Foxc1. Cells were pre-treated with DMSO or GSK-126 (2 μM) for 72 h & assayed for their capacity to invade through Matrigel. All assays were performed in triplicate. *p < 0.05, Student’s two tailed t-tests Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1268_goat-polyclonal-foxc1-antibody-3102024168211.jpg)
![Immunohistochemistry: Ly-6G/Ly-6C Antibody (NIMP-R14) [NB600-1387] - Histopathology of lung sections collected at 24 h pbi from mice co-infected with mouse adapted influenza A/Puerto Rico/8/34 (H1N1) (PR8) and type 2 pneumococcal strain D39 variants. Serial lung sections were subjected to immunohistochemistry (IHC) for pneumococcus using Rabbit Anti-Streptococcus pneumoniae Polyclonal Antibody (Catalog # NB100-64502) at 4 ug/mL or neutrophils using Rat Anti-Ly-6G/Ly-6C Monoclonal Antibody (Catalog # NB600-1387) at 2 ug/mL. Representative images at 4x magnification with 60x magnification inset are shown. Images courtesy of Dr. Amanda P. Smith, UTHSC, TN //doi.org/10.1101/659557](http://images.novusbio.com/fullsize/Ly-6G6C-Antibody-NIMP-R14-Immunohistochemistry-NB600-1387-img0006.jpg "Immunohistochemistry: Ly-6G/Ly-6C Antibody (NIMP-R14) [NB600-1387] - Histopathology of lung sections collected at 24 h pbi from mice co-infected with mouse adapted influenza A/Puerto Rico/8/34 (H1N1) (PR8) and type 2 pneumococcal strain D39 variants. Serial lung sections were subjected to immunohistochemistry (IHC) for pneumococcus using Rabbit Anti-Streptococcus pneumoniae Polyclonal Antibody (Catalog # NB100-64502) at 4 ug/mL or neutrophils using Rat Anti-Ly-6G/Ly-6C Monoclonal Antibody (Catalog # NB600-1387) at 2 ug/mL. Representative images at 4x magnification with 60x magnification inset are shown. Images courtesy of Dr. Amanda P. Smith, UTHSC, TN //doi.org/10.1101/659557")
![Immunohistochemistry-Frozen: Ly-6G/Ly-6C Antibody (NIMP-R14) [NB600-1387] - Staining for Ly-6G/Ly-6C FITC of frozen section of mouse spleen.](http://images.novusbio.com/fullsize/Ly-6G6C-Antibody-NIMP-R14-Immunohistochemistry-Frozen-NB600-1387-img0005.jpg)
![N/A beta Amyloid [HRP]](http://images.novusbio.com/fullsize2/Amyloid_beta_DAB140_ELISA_2623.jpg "N/A beta Amyloid [HRP]")
![N/A beta Amyloid [HRP]](http://images.novusbio.com/fullsize2/Amyloid_beta_DAB140_ELISA_2615.jpg)
![N/A beta Amyloid [HRP]](http://images.novusbio.com/fullsize2/Amyloid_beta_DAB140_ELISA_2616.jpg)
![N/A beta Amyloid [HRP]](http://images.novusbio.com/fullsize2/Amyloid_beta_DAB140_ELISA_2622.jpg)
![N/A MICB [Biotin]](http://images.novusbio.com/fullsize2/DATA_MICB_DY1599_ELISA_1682.jpg "N/A MICB [Biotin]")
![N/A Adiponectin/Acrp30 [HRP]](http://images.novusbio.com/fullsize2/DATA_Adiponectin_RRP300_ELISA_1096.jpg "N/A Adiponectin/Acrp30 [HRP]")
![N/A Adiponectin/Acrp30 [HRP]](http://images.novusbio.com/fullsize2/Adiponectin_RRP300_ELISA_363.jpg)
![N/A Insulin [HRP]](http://images.novusbio.com/fullsize2/DATA_Insulin_DINS00_ELISA_722.jpg "N/A Insulin [HRP]")
![N/A Insulin [HRP]](http://images.novusbio.com/fullsize2/Insulin_DINS00_ELISA_467.jpg)
![N/A Serpin E1/PAI-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_Serpin_E1_DY1786_ELISA_1715.jpg "N/A Serpin E1/PAI-1 [Biotin]")